Top Markets
#1 Black Phoenix Black Phoenix +324.80%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +57.52%
#4 Gold Park Gold Park +55.04%
#5 Acurast Acurast +30.18%
#6 BasedHype BasedHype +28.28%
#7 Cryptopia Cryptopia +22.67%
#8 Avantis Avantis +19.62%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.72%
#10 MYX Finance MYX Finance +16.77%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Thalia Therapeutics Plc Thalia Therapeutics Plc

Thalia Therapeutics Plc

THAT
Rank in Stocks #40845
Thalia Therapeutics Plc, a specialized pharmaceutical company established in... Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Share Price
$0.00884456
Market Cap
$73.61K
Change (1 day)
-3.70%
Change (1 year)
32.93%
Country
GB
Trade Thalia Therapeutics Plc (THAT)

Category

Healthcare
Revenue for Thalia Therapeutics Plc (THAT)
Revenue in Aug 2026 TTM: 0
According to Thalia Therapeutics Plc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Thalia Therapeutics Plc from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE